Press Releases

Company News
View Summary Genomic Health to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014
Oct 28, 2014
PDF 37.4 KB
View Summary Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients
Sep 29, 2014
PDF 18.3 KB
View Summary Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Sep 26, 2014
PDF 38.2 KB
View Summary New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires "Your Prostate Your Decision" Education Campaign with Baseball Hall-of-Famer Joe Torre
Sep 24, 2014
PDF 1.4 MB
View Summary Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics
Sep 12, 2014
PDF 55.3 KB
View Summary Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress
Sep 9, 2014
PDF 39.9 KB
View Summary Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference
Aug 8, 2014
PDF 35.7 KB
View Summary Genomic Health Announces Second Quarter 2014 Financial Results and Business Progress
Aug 7, 2014
PDF 50.8 KB
View Summary Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints
Aug 6, 2014
PDF 17.9 KB
View Summary Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014
Jul 31, 2014
PDF 54.7 KB
View Summary Genomic Health Announces Positive Topline Results of Second Large, Independent Validation Study of Oncotype DX® in DCIS Breast Cancer
Jun 11, 2014
PDF 55.9 KB
View Summary Multiple studies presented at 2014 ASCO® annual meeting reinforce unique, practice-changing value of Oncotype DX® breast cancer test
Jun 10, 2014
PDF 15.7 KB
View Summary Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers
Jun 3, 2014
PDF 37.0 KB
View Summary Multiple Studies Presented at ASCO® Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX® to Optimize Cancer Care
Jun 1, 2014
PDF 19.6 KB
View Summary Oncotype DX® Breast Cancer Test Predicts Late Recurrence Five to 15 Years Out
May 29, 2014
PDF 17.3 KB
View Summary Genomic Health to Present at Two Upcoming Investor Conferences
May 23, 2014
PDF 54.7 KB
View Summary Genomic Health Announces Data Reinforcing Robustness of Oncotype DX® Prostate Cancer Test at 2014 American Urological Association (AUA) Annual Meeting
May 20, 2014
PDF 56.1 KB
View Summary European Urology Published Groundbreaking Results from Three Studies Demonstrating Genomic Health's Oncotype DX® Test Predicts Prostate Cancer Aggressiveness at Diagnosis
May 16, 2014
PDF 18.9 KB
View Summary Genomic Health's Oncotype DX® Becomes First Multi-Gene Test for Cancer Management To Be Included in National Institutes of Health's (NIH) Genetic Testing Registry
May 14, 2014
PDF 56.5 KB
View Summary Genomic Health Announces First Quarter 2014 Financial Results and Business Progress
May 6, 2014
PDF 26.9 KB
Showing 1-20 of 293 Page: 1 2 3 4 5 ... 15  Next 20


  • ASCO® is a registered trademark of the American Society of Clinical Oncology. ASCO does not endorse any product or therapy. ® is a registered trademark of the National Comprehensive Cancer Network. The NCCN does not endorse any product or therapy.

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

Shareholder Tools



DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.